The Zacks Analyst Blog Highlights: Amgen, Celgene, Gilead Sciences, Vertex Pharmaceuticals and Nasdaq Biotechnology Index ETF


For Immediate Release

Chicago, IL – January 28, 2013 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Nasdaq Biotechnology Index ETF (IBB).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Friday’s Analyst Blog:

Safest Way to Play Biotech

Investing in biotechnology can be exciting, profitable, and loaded with land mines. For every company that hits the jackpot with a new marketable drug that makes it through the FDA gauntlets, there are a dozen stocks that run-up on such hopes and then crash and burn when the trials fail.

For this reason, some investors consider biotech stocks to be binary trades. Years ago I met some option traders who specialized in these "event" stocks and they called them "bipolar."

Whatever you want to call them, you have three basic routes to go if you still want to participate in biotech stocks:

1) Stick with large-cap, established businesses with deep and broad drug pipelines like Amgen (AMGN), Celgene (CELG) and Gilead Sciences (GILD).

2) Plow into lots of homework on the small and mid cap names with promising new research and good Zacks Rank earnings momentum. Note than many of these companies may be as yet unprofitable, but they still often earn a Zacks #1 or #2 rank if the trend of Earnings Estimate Revisions (:EER) is rising sufficiently.

If analysts suddenly see a company making it through some FDA hurdles of testing with one or more drugs for some form of cancer or other medical need that represents a significant market opportunity, they will begin raising estimates to account for this potential profitability. The takeover component of valuation is also a factor since big biopharma loves to scoop up hot new R&D.

Small and mid-cap biotech companies that I had some homework and investing success with in 2012 were Vertex Pharmaceuticals (VRTX), among others.

But even these stocks had wild swings and if you were on the wrong side of the earnings or FDA trend, you got burned. Which brings me to a third way to play biotech with less volatility and company-specific risk.

3) Buy the Nasdaq Biotechnology Index ETF (IBB). In March 2009, when it looked like stocks had made a trade-able bottom during the financial crisis, I wasn't out there picking individual stocks for people. But in my first appearance on business TV, I said it was a no-brainer for investors to put money into the future by buying two ETFs: Technology through XLK and Biotech through IBB, which was trading around $63 at the time.

The IBB is near its all-time highs above $148. Am I saying you should buy it now at $145 after you just missed the drop in November to $125?

Yes, I am. At least a partial allocation. If the broad market goes on to make new highs above S&P 1550, biotechs will be part of the story and the IBB will make new highs as well.

And in the big picture, if you want exposure to the future of drug medicine, this is one of the safest ways you are going to find. The current waves of growth here are in R&D that is exploiting new knowledge of the human genome to create new drugs and treatments.

Genetic targeting of diseases is a multi-billion dollar growth area that has large pharma firms like Pfizer, Bristol-Meyers and Merck scrambling to buy up younger companies with innovative science.

My best sense of the future of medicine is that 5-years from now more than half of the names in the top 10 of IBB will be different, but this index ETF with probably have net assets that put its price north of $200.

Even if I'm wrong, buying below $150 and trading the swings on the way to $175 in a few years isn't a bad way to participate either.


Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339



Read the analyst report on AMGN

Read the analyst report on CELG

Read the analyst report on GILD

Read the analyst report on VRTX

Read the analyst report on IBB

Zacks Investment Research

More From
View Comments

Recommended for You

  • First lady gets resume from girl with jobless dad

    WASHINGTON (AP) — Michelle Obama's annual question-and-answer session with the children of Executive Office employees took a serious turn Thursday when a 10-year-old girl in the front row told the first lady that her dad had been out of work for three years. Then the girl popped up to hand the…

    Associated Press
  • In Disney's shadow, homeless families struggle

    KISSIMMEE, Fla. (AP) — When they moved from Georgia to the theme park playground of central Florida four years ago, Anthony and Candice Johnson found work at a barbecue restaurant and a 7-Eleven. Their combined salaries nevertheless fell short of what they needed to rent an apartment, so the couple…

    Associated Press
  • Explore HKNB: Heidi Klum for New Balance

    Sport + Fashion. Fresh florals and iridescent accents. This season's Heidi Klum for New Balance collection takes you from the street to the studio.

    AdChoices New BalanceSponsored
  • Musk’s Tesla Income Plummets 99.9% to Less Than $70,000

    Elon Musk, Tesla Motors Inc. (TSLA) ’s chief executive and one of the wealthiest U.S. entrepreneurs, saw his take-home pay from the automaker plunge by more than 99.9 percent last year after a surge in his 2012 stock options. Compensation for the leader of the youngest publicly held U.S. automaker…

  • Putin Says Visa and MasterCard Will Lose Market Share

    Russian President Vladimir Putin said Visa Inc. (V) and MasterCard Inc. (MA) will lose market share in Russia after they blocked some transactions because of U.S. sanctions on individuals and banks. “We don’t see any steps to punish unconscionable partners, but they are undermining trust, hence…

  • Cramer: Tech stock heading to $70

    Jim Cramer looks at many metrics as he decides where to put money. And in the case of this tech firm, he's spotted something very bullish.

  • Play

    Best Credit Card for Travel Rewards?

    WSJ travel columnist Scott McCartney discusses the new Orbitz reward credit card and others that up the ante for the travel rewards category on Lunch Break.

    WSJ Live
  • Why it may be time to fold on casinos

    Casino stocks have been on a winning streak. But is it time to fold them?

    Talking Numbers
  • Here's why the biotech bounce may be short lived

    Will biotech get its mojo back or is it a dead cat bounce?

    Talking Numbers
  • iPhone, Android Phone and Tablet Repair Service

    Fix your cell phone or tablet fast with Werx Repair Services! We service most makes and models with rapid repair service!

    AdChoices WerxSponsored
  • Russia's Putin calls the Internet a 'CIA project'

    MOSCOW (AP) — President Vladimir Putin on Thursday called the Internet a CIA project and made comments about Russia's biggest search engine Yandex, sending the company's shares plummeting.

    Associated Press
  • Postal workers' unions protest Staples program

    CONCORD, N.H. (AP) — Postal workers in cities big and small protested in front of Staples stores on Thursday, objecting to the U.S. Postal Service's pilot program to open counters in stores, staffed with retail employees.

    Associated Press
  • North Dakota finds more radioactive oil waste

    BISMARCK, N.D. (AP) — North Dakota confirmed Thursday the discovery of a new radioactive dump of waste from oil drilling, and separately a company hired to clean up waste found in February at another location said it removed double the amount of radioactive material originally estimated to be there.

    Associated Press
  • Play

    Wall Street Bracing for Key Tech Earnings

    Polya Lesova takes a look at the markets, including three stocks to watch today. Photo: Andrew St. Clair for The Wall Street Journal.

    WSJ Live
  • Business Insider
  • Buffett disapproves of Coca-Cola's pay plan

    NEW YORK (AP) — Warren Buffett criticized Coca-Cola's pay plan for its executives on Wednesday.

    Associated Press
  • Northeastern University

    Earn an MBA Online from Northeastern University. Accredited by AACSB. No GMAT. You can build on your current career success. Get Info.

    AdChoices Northeastern UniversitySponsored
  • Pros and Cons of Paying Off Your Student Loans Early

    While paying off your student loans early seems like a no-brainer, it might not always be the best financial decision. Here are some of the pros and cons to paying off your student loans early, and some tips on how to pay them off. Paying off your student loan debt early can save you a good chunk…

    The Fiscal Times
  • US oil stockpiles hit record amid production boom

    US commercial oil stockpiles hit a new record last week on the strength of continued growth in oil and gas production in the world's biggest oil-consuming country. Commercial stocks rose 3.5 million barrels to 397.7 million barrels for the week ended April 18, according to US Energy Information…

  • United loses $609M in 1Q; fares don't cover costs

    United Airlines is the one U.S. carrier that can't seem to get its act together.

    Associated Press
  • Study: US manufacturers gaining competitiveness

    WASHINGTON (AP) — U.S. manufacturers have grown more competitive over the past decade compared with factories in China, Brazil and most of the world's other major economies.

    Associated Press
  • Amazon launches grocery service for Prime members

    NEW YORK (AP) — Amazon is taking aim at grocery stores and discounters like Wal-Mart with a grocery service that lets its Prime loyalty club members fill up to a 45-pound box with groceries and get it shipped for a flat rate of $5.99.

    Associated Press
  • Play

    Microsoft Posts Smaller-Than-Expected Profit Decline

    The first earnings report for Microsoft under new CEO Satya Nadella showed strong fiscal third-quarter sales from office tools, database and others programs for computer centers. WSJ's Shira Ovide and Scott Thurm report. (Photo: AP)

    WSJ Live
  • Gold Delta Skymiles Card

    30,000 bonus miles offer with the Gold Delta SkyMiles Credit Card.

    AdChoices DeltaSponsored